ReviewCureus2025
The Effects of Sodium-Glucose Co-transporter 2 Inhibitors on Cardiovascular Outcomes in Heart Failure: A Systematic Review and Meta-Analysis.
Review in Cureus, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Sodium-glucose co-transporter 2 (SGLT2) inhibitors, initially developed to treat type 2 diabetes mellitus, work by blocking SGLT2 proteins in the proximal convoluted tubules of the nephrons, thereby preventing glucose reabsorption into the bloodstream. Subsequently, its mechanism reveals additional cardiovascular and renal benefits, necessitating further investigation into its effects on heart failure. This condition affects millions and leads to diminished quality of life, frequent hospitalizations, and high mortality rates. This review aims to evaluate several large randomized controlled trials (RCTs) investigating the favourable outcomes of SGLT2 inhibitors on heart failure and its related variables, including hospitalizations secondary to the condition, mortality rate, kidney function, and left ventricular ejection fraction (LVEF). Nine RCTs were reviewed systematically and meta-analyzed to assess the effectiveness of SGLT2 inhibitors. A pooled risk ratio was calculated under a random-effects model, along with heterogeneity analysis, to summarize the overall effect across studies. The studies analyzed two primary clinical outcomes of mortality and rehospitalization due to heart failure. SGLT2 inhibitors were associated with a 20% relative reduction in mortality (risk ratio (RR) = 0.80) and a 24% relative risk reduction of rehospitalization due to heart failure (RR = 0.76). These findings support the cardioprotective effects of SGLT2 inhibitors, as well as significant reductions in hospitalization and mortality. The efficacy of SGLT2 inhibitors was observed across diverse demographic and clinical subgroups, supporting their role as a valuable therapeutic option for managing heart failure.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.